B+
Bull case
25%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
GMED
Globus MedicalANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Q2 showed broad operating momentum: revenue increased 5.9%, growth excluding Nevro was 9%, non-GAAP EPS rose 55.8%, and management raised full-year EPS guidance. Continued spine share gains, synergies and Excelsius3D commercialization could extend the earnings-growth cycle.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.4.
What can break
Excelsius3D has regulatory clearance for EU and UK commercialization, but hospital adoption, launch pace and revenue contribution have not been quantified.
Momentum
18
Value
65
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $88.00 · Bull $105.00 · Bear $62.00Analysis 2026-09-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $103.23
Why
Momentum18 · Δ7d -13.0
Value65 · Δ7d -0.0
Sentiment100 · Δ7d +10.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +10.4.
Contradictions & invalidation
- • Excelsius3D has regulatory clearance for EU and UK commercialization, but hospital adoption, launch pace and revenue contribution have not been quantified.
- • GAAP EPS declined 26.2% because the prior-year quarter included a $110.5 million Nevro bargain-purchase gain, making headline year-over-year comparisons potentially misleading.
- • US sales increased only 3%, while commercialization timing and revenue contribution from Excelsius3D are unquantified.
Catalyst clock
2026-12-31
Full-year 2026 guidance delivery
Lead driver: Sentiment · See AI snapshot
Momentum
18
9% active weight
Current posture
7d trendSoftening
Δ7d
-13.0
Δ21d
-34.5
Value
65
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+3.0
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+10.4
Δ21d
+25.8
Why this grade
Composite grade A. Momentum 17.9 / Value 65.3 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-12. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$88.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$62.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$11.43B
Beta
1.06
Shares Out
134.26M
P/E (TTM)
29.2
P/S (TTM)
4.37
P/FCF (TTM)
21.25
Rev YoY
+5.9%
EPS YoY
-25.8%
Gross Margin
+64.9%
Op Margin
+21.5%
Net Debt
-$437.8M
Current Ratio
4.62
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data